



Proteomics International

LABORATORIES LTD

**ASX Release
26 October 2021**

ASX code: PIQ

Proteomics International Laboratories Chairman Terry Sweet to retire at 2021 Annual General Meeting

Proteomics International Laboratories Ltd (ASX: PIQ) announces that its Non-Executive Chairman, Mr Terry Sweet, will retire at the close of the company's Annual General Meeting to be held on 25 November 2021.

Mr Sweet has served as Chairman since the company was incorporated in 2014.

Proteomics International Laboratories Ltd Managing Director Dr Richard Lipscombe said, *"Terry was instrumental in taking our company through its initial public listing as an R&D focused \$10 million dollar enterprise to the commercially driven \$100 million (circa) business we are today."*

"Under Terry's guidance we have built a fast-growing company positioned at the forefront of our sector in medical technology and specialist analytical services, and with our lead product, the world-first PromarkerD predictive test for diabetic kidney disease, commencing its global roll-out."

"We thank Terry wholeheartedly for his service and look forward to building on his pragmatic leadership and continuing our company's growth trajectory."

The Board has commenced the renewal process and intends to appoint new directors in due course.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com